IPCA Labs(Weekly): Critical Confluence at 50/100-WMA Support

245
IPCA Laboratories is currently testing a significant structural inflection point on the weekly timeframe. Price action is hovering at the convergence of the 50-Week and 100-Week Moving Averages (1,420 - 1,450 range). The resolution of this test will dictate the primary trend for the medium term, presenting two distinct, actionable scenarios.

Technical Context:
The 50-WMA and 100-WMA historically act as heavy dynamic support during primary uptrends. The stock is currently compressing at this confluence, requiring a definitive weekly close to confirm directional bias.

Scenario A: Bullish Continuation (Support Defended)
If buyers successfully defend this moving average confluence, the primary uptrend remains intact, setting up a continuation trade.
  • Thesis: Support holds, initiating a new impulsive wave upward.
  • Trigger: A strong, bullish weekly close above the 50-WMA and 100-WMA confluence.
  • Targets: Retest of structural resistance at 1,624 (Point X), followed by the All-Time High at 1,755.
  • Invalidation (SL): A close slightly below the 100-WMA or the recent structural swing low.

Scenario B: Bearish WXY Correction (Support Fails)
A breakdown below this major support confluence signals structural weakness and opens the door for a deeper macro correction.
  • Thesis: Failure to hold the 50/100-WMA confluence initiates a WXY double combo correction.
  • Trigger: A decisive weekly close below both the 50-WMA and 100-WMA.
  • Targets: Initial downside target at 1,168 (Wave W low). A sustained break below this level exposes the 1.0 Fibonacci extension at 1,036, which aligns with the deeper 200-WMA.
  • Invalidation (SL): A close back above the 50-WMA.

Summary:
Directional bias is currently neutral pending a weekly close. Market participants should wait for candle confirmation to dictate entry and adhere strictly to defined invalidation levels to manage downside risk.

Disclaimer: Pleae DYOR. Not a buy/sell recommendation. Educational only.

Thông báo miễn trừ trách nhiệm

Thông tin và các ấn phẩm này không nhằm mục đích, và không cấu thành, lời khuyên hoặc khuyến nghị về tài chính, đầu tư, giao dịch hay các loại khác do TradingView cung cấp hoặc xác nhận. Đọc thêm tại Điều khoản Sử dụng.